Source: Short video discussion 2022



Rating:

Share or cite this content

Citations should be made in the following way:
Katherine Myall (London, United Kingdom) & Emer Kelly (Dublin, Ireland). Time to breathe: How COVID-19 interacts with interstitial lung disease. Short video discussion 2022

Member's Comments

Surrayya Najeeb - 28.06.2022 17:03
Excellent discussion in minimum space of time.

Related content which might interest you: Interstitial lung disease (ILD) and multicompartment assessment of CTD: where should the respiratory physician begin? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020 Time as the fourth dimension of radiology: a patient with diffuse lung disease (interstitial lung disease) Source: International Congress 2016 – GR2 Radiology Year: 2016 Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)? Source: International Congress 2015 – IIPs: orphan Year: 2015 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Interstitial lung disease; where do we stand without histopathology? Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Changes in lung mechanics and gas exchange in patients with pulmonary sarcoidosis (PS) Source: International Congress 2014 – Innovative technology and techniques in respiratory function Year: 2014 What (and how) do we attain by performing surgical lung biopsy for interstitial lung disease? Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015 Intervention trials and ventilation distribution in mild cystic fibrosis lung disease: will it all come out in the wash? Source: Eur Respir J 2011; 37: 757-759 Year: 2011 Pattern of diffusion disturbance in patients with interstitial lung diseases (ILDs) Source: International Congress 2016 – The future of lung function is beginning now Year: 2016 Determining why patients with idiopathic pulmonary fibrosis (IPF) have difficulty performing gas transfer Source: Annual Congress 2013 –Airway calibre, airway challenge and assessment of oxygenation Year: 2013 Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean? Source: Eur Respir J, 55 (6) 2000894; 10.1183/13993003.00894-2020 Year: 2020 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Changes in pulmonary gas exchange in histiocytosis X patients depending on the type of ventilation disorders Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water Source: Eur Respir J 2013; 41: 781-783 Year: 2013 Multidisciplinary board for interstitial lung disease: Relevance for real life? Source: International Congress 2015 – New insights into IIPs Year: 2015 What is significant sleep disordered breathing in patients with interstitial lung disease? Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016